Type 1 Diabetes: Autoimmune Pathophysiology, Diagnosis & Modern Management

Type 1 diabetes mellitus (T1DM) is an autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency. Onset typically childhood/adolescence but can occur at any age.

Pathophysiology

  • Genetic susceptibility (HLA-DR3/DR4-DQ8) + environmental trigger (viral, dietary, microbiome) → autoimmunity.
  • Autoantibodies: GAD65, IA-2, ZnT8, insulin, ICA — present months/years before onset.
  • Progressive β-cell loss → insulinopenia → hyperglycemia → catabolism, ketogenesis.

Classic Presentation

  • Polyuria, polydipsia, polyphagia, weight loss
  • Fatigue, blurred vision, irritability
  • Diabetic ketoacidosis (DKA) at diagnosis in 30–40% (especially young children): nausea, vomiting, abdominal pain, Kussmaul breathing, altered consciousness.

Diagnosis

  • HbA1c ≥6.5%, fasting glucose ≥126, random ≥200 + symptoms, or OGTT ≥200.
  • Autoantibodies confirm autoimmune etiology.
  • C-peptide low/undetectable (vs. type 2).

Management

  • Insulin therapy: Basal-bolus (MDI: glargine/degudec + lispro/aspart/glulisine) or insulin pump (CSII).
  • Glucose monitoring: CGM (preferred) or SMBG.
  • Carbohydrate counting, dose adjustment.
  • Education: Sick-day rules, hypoglycemia treatment, ketone monitoring.
  • Screening: Thyroid (Hashimoto's), celiac, lipids, microalbumin, retinopathy, neuropathy.

Emerging Therapies

  • Teplizumab (anti-CD3) — delays onset in stage 2 (high-risk).
  • Islet transplantation, stem cell-derived β-cells (VX-880), artificial pancreas (closed-loop).

T1DM requires lifelong insulin, but technology and education enable full, active lives.

Diabetes - Related Articles